Asthma, Exercise-Induced Bronchoconstriction
Conditions
Keywords
Asthma, Exercise-Induced Bronchoconstriction, lipids, n-3 PUFA, airway inflammation, Bronchoconstriction
Brief summary
The primary aim of this study will be to evaluate the effects of Lyprinol® supplementation on airway inflammation and the bronchoconstrictor response to dry air hyperpnea in individuals with asthma. The investigators hypothesize that Lyprinol® supplementation, compared to placebo, will significantly attenuate airway inflammation and hyperpnea-induced bronchoconstriction in asthmatic individuals.
Detailed description
Our research group has shown, on numerous occasions that fish oil has a markedly protective effect in suppressing airway inflammation and exercise-induced bronchoconstriction in elite athletes and asthmatic individuals. Purified fish oil and the marine lipid fraction PCSO-524™ (Lyprinol™) have both been used in supplementation studies in asthma \[2, 10, 11\]. While fish oil is a rich source of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), Lyprinol® is a patented extract of stabilized lipids from the New Zealand green-lipped mussel, Perna canaliculus, combined with olive oil and vitamin E. EPA and DHA are the main ingredients of fish oil, and thus there will be similarities between Lyprinol and fish oil in terms of mechanism of action. Thus, we are aiming to show that Lyprinol® can modulate these inflammatory eicosanoids to exert anti-inflammatory effects.
Interventions
DIETARY_SUPPLEMENTLyprinol
8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
DIETARY_SUPPLEMENTPlacebo (Olive Oil)
8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
Sponsors
Pharmalink
Indiana University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
* Have been diagnosed with asthma and EIB. Evidence of a diagnosis of asthma will include medication use as well as history and symptoms as outlined in the NHLBI Guidelines for the Diagnosis and Management of Asthma. For the diagnosis of EIB, subjects must demonstrate a fall in FEV1 of ≥ 10% after dry air eucapnic voluntary hyperventilation (EVH), a simulated exercise challenge; FEV1 is a measure of lung function * Not currently be taking any fish oil supplements * Limit their fish consumption to 1 fish meal per week during the course of the study
Exclusion criteria
* Severe asthma is indicated. These subjects will be identified by a post-EVH drop in FEV1 that is greater than 50% during their first lab testing session or will have a history of severe asthma-related events such as hospitalizations or emergency room visits. Only mild to moderate asthmatics (i.e. subjects whose FEV1 drops by 10-50%) will be included in this study. * They taking currently taking asthma maintenance medications * They are pregnant * They have a history of hyperlipidemia (high cholesterol), hypertension, diabetes, bleeding disorder, delayed clotting time, or seizure disorder * They are allergic to shellfish, fish, corn, or soy products
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pulmonary Function (Percent Change in FEV1, measured in Liters) | 8 weeks | The percent change in FEV1 is the percent change in the volume of air exhaled during the first second of a forced exhalation as measured before and after the surrogate exercise challenge. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fraction of Exhaled Nitric Oxide | 8 weeks | The concentration of exhaled Nitric Oxide (measured as parts per billion) will be measured using a Nitric Oxide Analyzer. |
Countries
United States
Outcome results
None listed